New drug tested in brain tumor patients before surgery
NCT ID NCT05577416
Summary
This study tested a drug called AB-218 (Safusidenib) in patients with a specific genetic type of slow-growing brain tumor (IDH1 mutated low-grade glioma). The main goal was to see if it was practical to give the drug before planned surgery and to measure how much of the drug reached the tumor and affected it. After surgery, patients continued taking the drug to see if it helped control the tumor and was safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Royal Melbourne Hospital
Melbourne, Victoria, Australia
Conditions
Explore the condition pages connected to this study.